Bivatuzumab mertansine

Drug Profile

Bivatuzumab mertansine

Alternative Names: Anti-CD44v6-DM1 immunoconjugate; BIWI-1; Monoclonal antibody CD44v6-DM1 immunoconjugate

Latest Information Update: 31 Oct 2014

Price : $50

At a glance

  • Originator Boehringer Ingelheim; ImmunoGen
  • Developer Boehringer Ingelheim
  • Class Antineoplastics; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD44 antigen inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Head and neck cancer

Most Recent Events

  • 14 Feb 2005 Discontinued - Phase-I for Head and neck cancer in Germany (IV)
  • 04 Dec 2001 Preclinical development for Cancer in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top